Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$53.24 USD

53.24
3,973,139

+2.04 (3.98%)

Updated Jul 25, 2024 03:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (201 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Alnylam Reports Positive Data on Lumasiran in Renal Disease

Alnylam (ALNY) announces positive results from the ongoing study on lumasiran in Primary Hyperoxaluria Type 1 (PH1) patients.

    The Zacks Analyst Blog Highlights: Mastercard, VMware, Sanofi, Twitter and State Street

    The Zacks Analyst Blog Highlights: Mastercard, VMware, Sanofi, Twitter and State Street

      Indrajit Bandyopadhyay headshot

      3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry

      Though the large-cap pharma industry is struggling currently, there are a few stocks that are performing well.

        Kinjel Shah headshot

        5 Biotech Stocks to Boost Your Portfolio's Health This Year

        Though the biotech industry is down this year, there are still a few stocks which can strengthen your portfolio.

          The Zacks Analyst Blog Highlights: UnitedHealth, United Technologies, Eni, Sanofi and Discovery

          The Zacks Analyst Blog Highlights: UnitedHealth, United Technologies, Eni, Sanofi and Discovery

            Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx

            Label expansion of a few prominent drugs along with pipeline updates were the key areas of focus for investors in the biotech space.

              Mark Vickery headshot

              Top Research Reports for UnitedHealth, United Technologies & Eni

              Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), United Technologies (UTX) and Eni (E).

                Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data

                Amgen (AMGN) gets European Commission's approval to incorporate a new indication into the European label of its PCSK9 inhibitor, Repatha.

                  Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study

                  Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.

                    BioMarin Begins Mid Stage Study on Gene Therapy Candidate

                    BioMarin (BMRN) initiates a mid-stage study to evaluate its gene therapy candidate, valoctocogene roxaparvovec for treating in AAV5+ severe hemophilia A.

                      Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss

                      Alnylam (ALNY) incurs narrower-than-expected loss and missed revenue estimates in Q1. With several pipeline related events lined up and potential approval for patisiran, we expect investor focus to remain on the related updates.

                        Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View

                        Emergent's (EBS) earnings and revenues lag estimates in Q1. However, the top line improves marginally year over year, driven by higher contract manufacturing revenues.

                          Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q1

                          Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in Q1. The company remains on track to start a pivotal phase III study for CMB305 on patients with synovial sarcoma.

                            Regeneron (REGN) Q1 Earnings Top, Sales Lag, Updates View

                            Regeneron's (REGN) first-quarter results were mixed as earnings beat expectations while sales missed the same. Nevertheless, Eylea sales were impressive.

                              What's in the Offing for Regeneron (REGN) in Q1 Earnings?

                              Investors are expected to focus on Eylea's performance and Dupixent's uptake when Regeneron Pharmaceuticals, Inc. (REGN) reports first-quarter 2018 results on May 3.

                                Sanofi's (SNY) Earnings Beat Estimates in Q1, Sales Miss Mark

                                Sanofi (SNY) beat earnings but missed sales estimates in the first quarter of 2018 owing to exchange rate effects and struggling diabetes and cardiovascular unit.

                                  BioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales Beat

                                  BioMarin (BMRN) reported mixed first-quarter results with earnings missing estimates but sales beating the same.

                                    Amgen (AMGN) Earnings Beat Estimates in Q1, Revenues Up Y/Y

                                    Amgen (AMGN) impresses with better-than-estimated results on both counts but tweaks its sales guidance for 2018. Shares decline in after-hours trading.

                                      Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down

                                      Biogen's (BIIB) earnings beat estimates but sales miss the same marginally in Q1. The company's latest key drug Spinraza's tepid sales compares with its sequential tally.

                                        Shire (SHPG) Turns Down Takeda's Third Buyout Proposition

                                        Shire (SHPG) declines Takeda Pharmaceutical's third acquisition offer in a cash-stock deal.

                                          Sanofi to Divest European Generic Unit, Streamline Business

                                          Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.

                                            Mark Vickery headshot

                                            Top Analyst Reports for AbbVie, Berkshire & PepsiCo

                                            Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), Berkshire Hathaway (BRK.B) and PepsiCo (PEP).

                                              Alexion (ALXN) to Acquire Wilson Therapeutics for $855M

                                              Alexion (ALXN) announces that the company will acquire Sweden-based Wilson Therapeutics for $855 million, the latest company to join the ongoing acquisitions spree in the biotech sector.

                                                Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK's AMGN Drug Label Expansion

                                                The biotech sector grabbed headlines last week as Edge Therapeutics crashed on news of discontinuation of its phase III study while Amgen's Blincyto got FDA's nod for label expansion.

                                                  Sanofi's (SNY) Skin Cancer Candidate Filing Accepted in EU

                                                  Sanofi's (SNY) filing for its antibody cemiplimab for skin cancer and the label expansion of its marketed drug Dupixent for asthama wins acceptance from EMA.